Virtu Financial LLC Makes New Investment in Phio Pharmaceuticals Corp. (NASDAQ:PHIO)

Virtu Financial LLC purchased a new position in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned approximately 0.59% of Phio Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Phio Pharmaceuticals in a report on Wednesday, February 19th.

Phio Pharmaceuticals Price Performance

PHIO opened at $1.30 on Tuesday. The business has a fifty day moving average price of $1.68 and a 200 day moving average price of $2.40. Phio Pharmaceuticals Corp. has a 12 month low of $1.22 and a 12 month high of $9.79. The stock has a market capitalization of $8.95 million, a price-to-earnings ratio of -0.12 and a beta of 1.28.

Phio Pharmaceuticals Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.